High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study

Journal of Rheumatology

Volumn 23, Issue 1, 1996, Pages 71-75

  Schroeder, Johann O ^a,b   Zeuner, Rainald A ^a,b   Euler, Hans H ^a,b   Löffler, Helmut ^a,b  

^a UNIVERSITY OF KIEL   (Germany)

^b Department of Internal Medicine ^*  (Germany)

Author keywords

Disease activity; dsDNA antibodies; Intravenous immunoglobulins; Pilot study; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN 7S; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; CLINICAL PROTOCOLS; COMPLEMENT C3; COMPLEMENT C4; DNA DAMAGE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PILOT PROJECTS; PLATELET COUNT; SEVERITY OF ILLNESS INDEX;

EID: 0030068117     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Imbach P, Barandun S, d'Apuzzo V, et al. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31.
2. van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl J Med 1992;326:1123-9.
3. Newburger JW, Takahashi M, Burns JC, et al: The treatment of Kawasaki syndrome with intravenous gammaglobulin. New Engl J Med 1986;315-341-7.
4. Dalakas MC, Illa I, Dambrosia JM, et al: A controlled trial of high-dose intravenous immunoglobulin infusion as treatment for dermatomyositis. New Engl J Med 1993;329:1993-2000.
5. Corvetta A, Dell Bitta R, Gabrielli A, Spaeth PJ, Danieli G Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: Report of three cases. Clin Exp Rheumatol 1989; 7:295-9.
6. Akashi K, Nagasawa K, Mayumi T, Yokota E, Oochi N, Kusaba T: Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins. J Rheumatol 1990;17:375-9.
7. Sturfelt G, Mousa F, Jonsson H, Nived O, Thysell H, Wollheim F: Recurrent cerebral infarction and the antiphospholipid syndrome: Effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheum Dis 1990;49:939-41.
8. Ben-Chetrit E, Putterman C, Naparstek Y: Lupus refractory pleural effusion: Transient response to intravenous immunoglobulins. J Rheumatol 1991;18:1635-7.
9. Cohen MG, Li EK: Limited effects of intravenous IgG in treating systemic lupus erythematosus-associated thrombocytopenia (letter). Arthritis Rheum 1991;34:787-8.
10. ter Borg EJ, Callenberg CGM: Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin. Ann Rheum Dis 1992;51:1149-51.
11. Tomer Y, Shoenfeld Y: Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992;10-391-3.
12. Winder A, Molad Y, Ostfeld I, Kenet G, Pinkhas J, Sidi Y: Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: Report of 2 cases. J Rheumatol 1993;20:495-8.
13. Lin CY, Hsu HC, Chiang H: Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989;53-303-10.
14. Mater WP, Gordon DS, Howard RF, et al: Intravenous immunoglobulin therapy in systemic lupus erythematosus associated thrombocytopenia. Arthritis Rheum 1990;53:1233-9.
15. Pirner K, Rubbert A, Burmester GR, Kalden JR, Manger B: Intravenös verabreichte Immunglobuline beim systemischen Lupus erythematodes: Literaturübersicht und erste klinische Erfahrungen. Infusionsther Transfusionsmed 1993;(suppl 1)20:131-6.
16. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R: Long term ivIg treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:163-8.
17. Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18
18. Corziliius M, Euler HH, Schroeder JO, Liang MH, Larson MG: Comparative responsiveness of three disease activity indices for systemic lupus erythematosus (SLE). Arthritis Rheum 1993; (suppl 9)36:184.
19. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Gronski P, Hofstaetter T, Kanzy EJ, Lüben G, Seiler FR: S-sulfonation: A reversible chemical modification of human immunoglobulins permitting intravenous application. I. Physiochemical and binding properties of S-sulfonated and reconstituted IgG. Vox Sang 1983;45.144-54.
21. Wilcoxon F: Individual comparisons by ranking methods. Biometrics 1945;1:80-3.
22. Stewart RRC, Winney RJ, Cash JD: Renal toxicity of intravenous immunoglobulin (letter). Vox Sang 1993;65:244.
23. Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K: High-dose intravenous IgG treatment and renal function. Lancet 1991;337:457-8.
24. Pasatiempo AMG, Kroser JA, Rudnick M, Hoffmann BI: Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994;21:347-9.
25. Dwyer JM: Drug therapy. Manipulating the immune system with immune globulin. New Engl J Med 1992;326:107-16
26. Rossi F, Kazatchkine MD: Antiidiotypes against autoantibodies in pooled normal polyspecific Ig. J Immunol 1989;143:4104-9.
27. Evans MJ, Suenaga R, Abdou NI: Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin. J Clin Immunol 1991;11:291-5.
28. Basta M, Fries JF. Frank MM: High doses of intravenous immunoglobulin inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991;77:376-80.
29. Macey MG, Newland AC: CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol 1990;76:513-20.